Abeona rises after adding New York treatment center for gene therapy

Shares of drugmaker Abeona Therapeutics ABEO.O rise 2.07% to $4.67

Co says it has added NewYork-Presbyterian/Columbia University Irving Medical Center as a treatment center for its gene therapy, Zevaskyn, expanding access in New York and the Northeast

Says the site is its fifth qualified treatment center

Zevaskyn is the only gene therapy approved for wounds in adults and children with recessive dystrophic epidermolysis bullosa, a rare inherited skin disease that causes severe blistering and hard-to-heal wounds - ABEO

Says the treatment uses a patient's own skin cells, modified to restore the missing type VII collagen needed to hold skin layers together

ABEO shares were down over 5% in 2025